Cotrimoxazole myelotoxicity in hematopoietic SCT recipients: time for reappraisal.

摘要

Cotrimoxazole, a drug combination of Trimethoprim, a folate antagonist, and Sulfamethoxazole, a sulfonamide, is commonly used in recipients of allogeneic hematopoietic SCT (HSCT) as prophylaxis against Pneumocystis jirovecii infection and for reactivation of Toxoplasmosis most commonly at a dose of 3 x 160/800 mg per week with or without folinic acid supplementation. Cotrimoxazole is known for myelotoxicity, especially after long-term administration as prophylaxis in HIV patients,9 and is therefore used cautiously after HSCT. The impact of this toxicity on neutrophil and platelet engraftment and duration of neutropenia/thrombocytopenia after allogeneic HSCT has not been determined.